Omada Health releases new data on its GLP-1 companion program
Omada Health (OMDA) released new data demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss. Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings. Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks, 42% to 80%, and 24 weeks, 33% to 74%, after starting GLP-1s. In contrast, members included in this analysis of Omada's Enhanced GLP-1 Care Track demonstrated higher persistence rates-94% through 12 weeks and 84% through 24 weeks
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on OMDA:
Disclaimer & DisclosureReport an Issue
Omada Health Completes Successful Initial Public Offering
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
The J. M. Smucker Company (SJM) I Told Them Not To Buy Twinkies!, Says Jim Cramer
The J. M. Smucker Company (NYSE:SJM) is one of the . The J. M. Smucker Company (NYSE:SJM) is a major American food products company. As has been the case with other food companies, such as Pepsi, investors are worried about the firm suffering in the aftermath of the GLP-1 wave in America. The J. M. Smucker Company (NYSE:SJM)'s shares have lost 12.9% year-to-date primarily due to a disastrous 15.6% dip in June. The shares fell after the firm's latest earnings report disappointed investors on the guidance front. The J. M. Smucker Company (NYSE:SJM) guided $9 in midpoint full-year earnings while analysts had penciled in $10.26. In his remarks, Cramer discussed an overlooked factor behind the earnings disaster: '[After Faber pointed out the shares were down 6% and the firm had missed guidance] Yeah I didn't really uh, that was quite opaque . . it's not clear what it is. I'll tell you what is clear. 980 million dollar impairment charge for Hostess Twinkies bought for 5.6 billion at the beginning of what is called GLP-1. I told them not to do it!' The J. M. Smucker Company (NYSE:SJM)'s management warned about tariffs in its latest earnings call. Here is what they said: 'As a domestic food producer, we are relatively less exposed to tariffs compared to other industries. That said, the current U.S. tariff impact on green coffee is our largest exposure that we will manage on top of navigating record-high costs for the commodity. Green coffee is an unavailable natural resource that cannot be grown in the continental U.S. due to its reliance on a tropical climate. We currently purchase approximately 500 million pounds of green coffee annually, with the majority coming from Brazil and Vietnam, the 2 largest coffee producing countries. Outside of coffee, the vast majority of our U.S. production is sourced domestically. However, there is some sourcing of finished goods and ingredients that are subject to tariffs as things stand today. A wholesaler distributing peanut butter, fruit spreads and specialty spreads to a retailer. This has been factored into our outlook, and we are working to mitigate these cost increases through a combination of alternative sourcing strategies, supply chain optimization, and responsible pricing.' While we acknowledge the potential of SJM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
McDonald's Corporation (MCD): Those Who Downgrade The Stock Will Be 'Wrong,' Says Jim Cramer
McDonald's Corporation (NYSE:MCD) is one of the . McDonald's Corporation (NYSE:MCD) is a frequent feature of Cramer's morning show. The fast food giant's shares have lost 1.7% year-to-date primarily due to 5% since mid-June. McDonald's Corporation (NYSE:MCD), like other food companies, is at the risk of its business being disrupted or shrunk due to GLP-1 drugs as they help users control their hunger. The shares fell in June after a downgrade from Redburn. Commenting on stock downgrades, Cramer outlined: '[On a third downgrade based on a lower value proposition than before in case of a recession] They're gonna be wrong. They are gonna be wrong. Okay Kempczinski is under fire because of the chicken strips and then next week we'll all get chicken strips with the wraps. You want to see how ugly chicken strips are, they're ugly, they don't look like, I don't know what they look like. . .but I know that Chris will kill that if it doesn't sell . . . And people are really underrating Chris. He is a great CEO. McDonald's has a history of getting rid of CEOs if they don't work, getting rid of dishes if they don't work. Earlier, Cramer discussed Morgan Stanley and Loop Capital downgrading McDonald's Corporation (NYSE:MCD)'s stock: 'It amazes me that analysts refuse to learn from their mistakes that some stocks should not be taken off the buy list. Today, Morgan Stanley downgraded the stock of McDonald's, saying it's arguably too expensive and that it will probably not be insulated from some structural pressures on fast food. Now, with the stock at 25 times earnings, consensus estimate's too high. Morgan Stanley moved [it] to Equal Weight or Hold. [The] stock dropped $2 and 58 cents or 0.84% on that. A cook in a busy kitchen assembling cheeseburgers for orders. Listen, McDonald's is an amazing company. It didn't become amazing because it stuck with bad ideas… The strength of McDonald's is that they don't fight battles they can't win. When something doesn't work, they just dump it and they move on. Which is why I say you downgrade a stock like McDonald's at your own peril.' While we acknowledge the potential of MCD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting' data
H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug's 'highly differentiated mechanism of action' compared to currently approved therapies, H.C. Wainwright believes rezpeg 'has the potential to reshape the treatment landscape' for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a 'paradigm-shifting' atopic dermatitis drug 'has arrived.' The stock in midday trading is up 134%, or $12.82, to $22.36. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on NKTR: Disclaimer & DisclosureReport an Issue Nektar price target raised to $120 from $6.50 at H.C. Wainwright Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? Nektar jumps 130% to $21.90 after atopic dermatitis study success Nektar Therapeutics Announces Positive Phase 2b Trial Results Nektar's rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
